Bill & Melinda Gates Foundation

Likarda is a biotech company focused on advancing cell therapies through innovative delivery technologies. Its proprietary Core-Shell Spherification® platform utilizes biocompatible hydrogel materials, such as Hyaluronic Acid and PEG, to create customizable microcapsules that house cell-based therapies. This platform addresses the unique requirements of various cell therapies, enabling applications in the treatment of diabetes, osteoarthritis, and joint pain. For diabetes, Likarda is developing methods to deliver islet-like cells, which have shown promising results in pre-clinical testing with animal models. In the case of osteoarthritis, encapsulated stem cells are designed for injection into the knee, providing a slow-release treatment that alleviates joint pain and promotes healing over several weeks. Likarda's versatility allows for both durable and degradable formulations, enhancing the efficacy of cell-based treatments. The company has gained recognition for its innovation, having been named one of the "50 Most Promising Start-Ups in the World" during Global Entrepreneurship Week, and has secured over $8 million in funding through various sources.

Leinco Technologies is a company that specializes in the development of high-purity monoclonal antibodies, proteins, and various reagents specifically for the diagnostic and biopharmaceutical industries. They provide a range of services, including in vitro antibody and protein production, antibody conjugations, and cell banking. Leinco Technologies focuses on augmenting the early discovery process in life science research and diagnostics, as well as contributing to the innovative development of protein therapeutics. Their expertise in optimizing and adapting products enables clients to effectively meet their research and development needs.

ReciBioPharm operates as a biologics company. ReciBioPharm is a division of Recipharm.

Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the precise insertion of therapeutic messages into the human genome. This innovative approach aims to address diseases at their source by enabling both small and large genetic alterations. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics seeks to overcome existing limitations in these fields, enhancing their efficacy and reach. Founded by Flagship Pioneering, the company aspires to establish a new category in genetic medicine that can significantly improve patient outcomes and transform healthcare.

VitriVax is a biotechnology startup based in Boulder, Colorado, dedicated to advancing vaccine formulation through its innovative technology platform. The company has developed proprietary atomic layering thermostable antigen and adjuvant (ALTA) technology, which aims to enhance the effectiveness, affordability, and accessibility of both human and animal vaccines worldwide. This technology allows for the creation of thermostable, single-shot vaccines that can maintain or improve immune responses, enabling the incorporation of prime and booster doses in a single administration. With significant financial backing from various organizations, including the Bill and Melinda Gates Foundation, VitriVax addresses critical barriers to global vaccination, striving to improve public health outcomes.

BioSurfaces is a developer of medical devices specializing in tissue engineering and personal care products. The company leverages advanced electrospinning technology to produce nanofibrous materials that facilitate controlled drug delivery and enhance healing at the implant site. By utilizing a room-temperature electrospinning process, BioSurfaces enables the integration of drug loading within each fiber, creating a reservoir for sustained drug release. This innovative approach allows for the creation of devices and coatings as thin as 10 micrometers, making it possible to treat diseases directly at the site of implantation. The company aims to provide next-generation solutions for the medical and personal care markets, focusing on improving patient outcomes through effective disease treatment and tissue regeneration.

Freya Biosciences is a clinical-stage women's health company headquartered in Copenhagen and Boston, specializing in the development of microbial immunotherapies. The company focuses on addressing significant unmet medical needs across various indications by utilizing a proprietary platform to engineer and manufacture live microbes. These engineered microbes are designed to be both safe and effective for human use, facilitating the creation of innovative treatments for a range of diseases.

La Ruche Health is a healthcare technology company that facilitates access to both virtual and at-home healthcare services. It offers a platform that integrates health AI with text, voice, and image capabilities, enabling patients to receive medical advice and easily book services and lab tests through applications like iOS, Android, and WhatsApp. Recognizing WhatsApp as a key distribution channel, La Ruche Health was the first to incorporate generative AI into this platform, creating an organic conversational experience that enhances accessibility for diverse user groups, including those with low literacy. Additionally, the company's medical record management system supports healthcare teams in managing and exchanging medical data, while its wellness marketplace promotes affordable access to modern health services. This comprehensive approach allows patients to connect with healthcare facilities and improves decision-making at the point of care.

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Menlo Park, California, focused on the research, development, and commercialization of innovative medicines for infectious diseases. Founded in 2017, the company aims to address significant unmet medical needs through its development of novel therapeutics. Its lead product candidate, epetraborole, is a once-daily oral treatment designed for patients suffering from chronic non-tuberculous mycobacterial lung disease. AN2 Therapeutics is committed to leveraging advanced biomedical expertise to create transformative solutions for patients dealing with serious and rare infectious diseases. The company has also established a strategic partnership with Brii Biosciences to enhance its development efforts.

CanSino Biologics focuses on the R&D, manufacturing, and commercialization of vaccine products for human use. These vaccine products include pneumococcal polysaccharide and conjugate vaccines, and a DTcP-based combo, and other items. It is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine.

Eyam Vaccines and Immunotherapeutics is a life science and medical research company focused on the development of vaccines to combat infectious diseases. The company specializes in researching vaccines that target the spike glycoprotein, which is crucial for generating neutralizing antibodies against pathogens such as the novel coronavirus. Eyam employs a self-amplifying vaccine platform that enables the design of low-dose vaccines with advanced targeting capabilities, ensuring comprehensive protection, including against emerging variants. Through its innovative approach, the company aims to address pressing healthcare challenges and enhance public health outcomes.

Field develops innovative pharmaceutical supply-chain technology aimed at enhancing healthcare delivery in rapidly growing regions. The company focuses on digitizing and modernizing supply chains, making them more effective and scalable. By providing accessible and efficient solutions, Field strengthens partnerships with communities and supports the promise of healthcare for millions. Its platform is designed to empower governments and businesses, transforming the way healthcare services are provided globally.

Immorna is a biotechnology company focused on the development of RNA-based therapeutics and vaccines. The company employs various RNA platforms, including conventional, self-replicating, and circular RNA, to create innovative treatment solutions. Immorna has established a comprehensive management console that supports RNA synthesis, purification, and analytical testing, which is designed for both clinical and commercial applications. With advanced screening tools, the company has developed a range of RNA delivery vehicles, including polymers and lipid nanoparticles that utilize proprietary ionizable cationic lipids. This portfolio positions Immorna to effectively address a variety of medical needs through its cutting-edge RNA technology.

Noze is a pioneering company in digital odor perception, recognized for creating an advanced digital nose that accurately detects and identifies odors in various real-world contexts. Leveraging cutting-edge machine perception technology and a specialized sensor developed from NASA innovations, Noze aims to enhance human health and wellbeing. The company's technology mimics the human olfactory system, allowing it to gather data on air quality and chemical footprints based on scent. This enables healthcare providers to monitor and predict health changes, diagnose diseases, and perform routine screenings through breath-based odor biomarkers. Ultimately, Noze is dedicated to facilitating real-time disease detection at any point-of-care, thereby significantly improving patient outcomes.

Ethris GmbH is a biotechnology company based in Planegg, Germany, specializing in the development of innovative therapeutic solutions for diseases with unmet medical needs. The company has a focus on transcript therapeutics, particularly through its SNIM RNA platform, which offers a novel approach to treating various conditions by enabling the production of therapeutic proteins within the patient’s body. This platform presents an alternative to traditional recombinant protein and gene therapies, addressing a range of diseases, including rare and genetically predetermined conditions. Ethris also develops Magnetovax, a personalized tumor vaccine platform that utilizes magnetic fields for localized activation in tumors. The company has established strategic research collaborations with major pharmaceutical firms, enhancing its capabilities in regenerative medicine and therapeutic development. Founded in 2009, Ethris continues to advance its technologies to meet diverse medical needs.

Nanite is a biotechnology company focused on non-viral gene delivery through the development of programmable polymer nanoparticles. Utilizing an artificial intelligence-driven platform, Nanite integrates advanced high-throughput experimental and computational techniques to create tailored delivery vehicles capable of transporting a diverse array of genetic materials with specific targeting capabilities. This innovative approach aims to assist scientists in functional chemistry by providing therapeutically relevant solutions for gene delivery, enhancing the potential for various medical applications and indications.

Owlstone Medical, established in 2003 and headquartered in Cambridge, UK, specializes in developing and commercializing breathalyzers for clinical diagnostics and precision medicine. The company's core technology, FAIMS, enables the detection of volatile organic compounds in breath, facilitating the discovery of non-invasive biomarkers for various diseases. Owlstone Medical's product portfolio includes breath samplers like ReCIVA and CASPER, as well as analytical tools such as Lonestar and ATLAS, catering to applications like lung cancer, asthma, and gastrointestinal disorders. The company collaborates with market leaders to integrate its technology into next-generation chemical sensing products and has received funding from the UK's Department of Defense to develop a handheld device for enhanced sensitivity and selectivity. Owlstone Medical aims to become a global leader in non-invasive diagnostics, with a focus on early disease detection and a pipeline of medical applications, including colon and lung cancer screening.

Owlstone Medical, established in 2003 and headquartered in Cambridge, UK, specializes in developing and commercializing breathalyzers for clinical diagnostics and precision medicine. The company's core technology, FAIMS, enables the detection of volatile organic compounds in breath, facilitating the discovery of non-invasive biomarkers for various diseases. Owlstone Medical's product portfolio includes breath samplers like ReCIVA and CASPER, as well as analytical tools such as Lonestar and ATLAS, catering to applications like lung cancer, asthma, and gastrointestinal disorders. The company collaborates with market leaders to integrate its technology into next-generation chemical sensing products and has received funding from the UK's Department of Defense to develop a handheld device for enhanced sensitivity and selectivity. Owlstone Medical aims to become a global leader in non-invasive diagnostics, with a focus on early disease detection and a pipeline of medical applications, including colon and lung cancer screening.

Sibel Health, established in 2018 and headquartered in Evanston, Illinois, specializes in advanced monitoring solutions for healthcare. The company develops soft, flexible sensors that provide clinical-grade, wireless vital signs monitoring, including heart rate, respiratory rate, skin temperature, body position, and activities. These sensors are designed for use on patients and pregnant mothers, offering a comprehensive physiological monitoring platform with advanced analytics for both clinical care and research applications. Sibel Health's innovative digital health solutions are tailored for the pharmaceutical and clinical research sectors, enhancing healthcare delivery and patient outcomes.

Corner Therapeutics is a biotechnology research company focused on advancing immunotherapy solutions. The company specializes in stimulating exceptional memory T cells to achieve lifelong immunity. It has developed a versatile dendritic cell hyperactivation (hDC) platform that induces strong T-cell responses, aiming to deliver robust and durable immunity against a wide array of cancers and infectious diseases. By providing these innovative technologies, Corner Therapeutics enables healthcare providers to enhance immune responses and promote long-lasting immunity, positioning itself at the forefront of immunotherapy research.

Ginkgo Bioworks is a biotechnology firm based in Boston, Massachusetts, that specializes in designing, engineering, and developing custom microbes and organisms for various applications. Founded in 2008, the company focuses on discovering and licensing molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. In addition to these capabilities, Ginkgo Bioworks provides probiotic bacteria that help protect against infections and creates extensive libraries of molecules. The firm operates across multiple markets, including cultured ingredients, carbon mitigation, probiotics, and natural product discovery. It has reorganized its operations into two primary segments: Cell Engineering and Biosecurity, with a significant portion of its revenue generated from biosecurity-related data analytics and services.

Noze is a pioneering company in digital odor perception, recognized for creating an advanced digital nose that accurately detects and identifies odors in various real-world contexts. Leveraging cutting-edge machine perception technology and a specialized sensor developed from NASA innovations, Noze aims to enhance human health and wellbeing. The company's technology mimics the human olfactory system, allowing it to gather data on air quality and chemical footprints based on scent. This enables healthcare providers to monitor and predict health changes, diagnose diseases, and perform routine screenings through breath-based odor biomarkers. Ultimately, Noze is dedicated to facilitating real-time disease detection at any point-of-care, thereby significantly improving patient outcomes.

LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"​) and Oral Thin Films ("OTF"​) for the pharmaceutical industry. While we continuously refine our TTS and OTF technologies further, we also research complementary Micro Array Patches for the transdermal delivery of large molecule, biological actives. Incorporated in 1984, we operate today from two sites in Andernach, Germany and West Caldwell/NJ, USA, plus representative office in Shanghai/China.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

Brightseed, Inc. is a pioneering biosciences company based in San Francisco, California, founded in 2017. It specializes in the discovery of bioactive compounds in plants that have beneficial effects on human health, particularly for chronic disease management. Utilizing its proprietary Forager platform, which incorporates artificial intelligence and machine learning, Brightseed accelerates the identification and validation of these naturally occurring compounds, transforming what was once a lengthy process into a matter of months. By mapping bioactives to specific health outcomes, Brightseed provides valuable insights and science-backed solutions to partners across the consumer health continuum. The company's innovative approach aims to illuminate the connections between nature and human health, ultimately improving quality of life and addressing health challenges through the exploration of previously uncharted plant compounds.

Ginkgo Bioworks is a biotechnology firm based in Boston, Massachusetts, that specializes in designing, engineering, and developing custom microbes and organisms for various applications. Founded in 2008, the company focuses on discovering and licensing molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. In addition to these capabilities, Ginkgo Bioworks provides probiotic bacteria that help protect against infections and creates extensive libraries of molecules. The firm operates across multiple markets, including cultured ingredients, carbon mitigation, probiotics, and natural product discovery. It has reorganized its operations into two primary segments: Cell Engineering and Biosecurity, with a significant portion of its revenue generated from biosecurity-related data analytics and services.

LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"​) and Oral Thin Films ("OTF"​) for the pharmaceutical industry. While we continuously refine our TTS and OTF technologies further, we also research complementary Micro Array Patches for the transdermal delivery of large molecule, biological actives. Incorporated in 1984, we operate today from two sites in Andernach, Germany and West Caldwell/NJ, USA, plus representative office in Shanghai/China.

VitriVax is a biotechnology startup based in Boulder, Colorado, dedicated to advancing vaccine formulation through its innovative technology platform. The company has developed proprietary atomic layering thermostable antigen and adjuvant (ALTA) technology, which aims to enhance the effectiveness, affordability, and accessibility of both human and animal vaccines worldwide. This technology allows for the creation of thermostable, single-shot vaccines that can maintain or improve immune responses, enabling the incorporation of prime and booster doses in a single administration. With significant financial backing from various organizations, including the Bill and Melinda Gates Foundation, VitriVax addresses critical barriers to global vaccination, striving to improve public health outcomes.

Philips, established in 1891, is a Dutch diversified technology company that focuses on improving people's health and well-being through meaningful innovation. The company operates in three segments: Diagnosis & Treatment, Connected Care, and Personal Health. Philips Healthcare, a division of Philips, is a leader in diagnostic imaging, image-guided therapy, patient monitoring, health informatics, consumer health, and home care. It offers a wide range of products such as CT scanners, MRI machines, ultrasound equipment, and more, aiming to enhance preventive care, diagnosis, and treatment. Additionally, Philips Research drives innovation across these segments, while the Philips Foundation focuses on reducing healthcare inequality through access to quality care for disadvantaged communities. The company also provides lighting solutions and consumer lifestyle products, including personal care and oral healthcare items.

BiomEdit is an innovation company focused on developing novel probiotics, microbiome-derived bioactives, and engineered microbial medicines to meet unmet needs in animal health. The company aims to address significant challenges in animal agriculture and food security by harnessing the potential of the microbiome. BiomEdit employs a unique platform that combines high-throughput sequencing and data analytics to efficiently discover and screen new probiotic species and bioactive molecules. These innovations can be engineered for enhanced stability and improved production of beneficial metabolites or immune-modulating proteins. The resulting probiotics and microbially-derived compounds represent advanced solutions designed to promote animal health while minimizing reliance on antibiotics.

Axmed is a business focuses on LMICs and strengthens the purchasing power of these markets to ensure the supply of cost-effective, high-quality medicines. We partner exclusively with authorized, high-quality pharmaceutical companies and certified caregivers to accelerate access to medicines.

CanSino Biologics Inc. is a biotechnology company based in Tianjin, China, focused on the research, development, manufacturing, and commercialization of vaccines. The company is actively developing a range of vaccines, including those for Ebola, meningitis, pertussis, and pneumococcal diseases, with multiple candidates currently in various phases of clinical trials. Notable products under development include the recombinant coronavirus vaccine Ad5-nCov, as well as several preclinical stage vaccines targeting adenovirus, Zika virus, meningitis, shingles, and polio. CanSino collaborates with the National Research Council of Canada to advance COVID-19 vaccine initiatives and has a co-development agreement with Precision NanoSystems to create an mRNA lipid nanoparticle vaccine against COVID-19. Founded in 2009, CanSino aims to meet the unmet medical needs in China and other emerging markets by providing high-quality vaccines at affordable prices.

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Menlo Park, California, focused on the research, development, and commercialization of innovative medicines for infectious diseases. Founded in 2017, the company aims to address significant unmet medical needs through its development of novel therapeutics. Its lead product candidate, epetraborole, is a once-daily oral treatment designed for patients suffering from chronic non-tuberculous mycobacterial lung disease. AN2 Therapeutics is committed to leveraging advanced biomedical expertise to create transformative solutions for patients dealing with serious and rare infectious diseases. The company has also established a strategic partnership with Brii Biosciences to enhance its development efforts.

GE Healthcare is a multinational healthcare company based in Chicago, Illinois, that specializes in manufacturing a diverse range of medical equipment and technologies. Founded in 1892, the company offers products and services including medical imaging, information technologies, medical diagnostics, and patient monitoring systems. GE Healthcare also supports drug discovery and biopharmaceutical manufacturing through intelligent devices and data analytics. The company aims to enhance patient care and outcomes by providing innovative healthcare solutions utilized in hospitals, clinics, research institutions, and pharmaceutical companies globally. By focusing on precision health and digitizing healthcare, GE Healthcare seeks to improve productivity and health outcomes for patients and healthcare providers alike. Additionally, the company pursues an aggressive acquisition strategy to strengthen its presence in emerging markets and expand its life sciences portfolio.

The American University of Beirut (AUB) is a prominent educational institution established in 1866, originally known as Syrian Protestant College until its name change in 1920. Located in Beirut, Lebanon, AUB follows the American liberal arts model and offers a comprehensive range of programs, including bachelor's, master's, M.D., and Ph.D. degrees across six faculties: Agricultural and Food Sciences, Arts and Sciences, Engineering and Architecture, Health Sciences, Medicine, and Business. The university promotes a teaching-centered research environment and emphasizes critical thinking, personal integrity, and civic responsibility among its approximately 8,000 students. With a faculty of around 800, AUB maintains a student-faculty ratio of 11.2 to 1. The institution is accredited by the Commission on Higher Education of the Middle States Association of Colleges and Schools in the United States and has been coeducational since 1922, with a balanced student demographic of 50 percent male and 50 percent female. The primary language of instruction is English, except for courses offered in the Arabic Department and other language programs.

EHA Clinics is a healthcare service provider focused on delivering accessible, effective, and affordable quality healthcare. The company offers a comprehensive network that includes integrated services such as routine medical care, laboratory services, pharmacy, optometry, dental care, urgent care, and specialist consultations. EHA Clinics aims to enhance the healthcare experience for its members by utilizing technology and a skilled team, ensuring improved health outcomes and cost efficiency. Their services are available 24/7 through a variety of platforms, including physical locations, telehealth virtual visits, and home care, allowing members to receive timely and convenient medical attention.

Bactolife is a company focused on addressing the global challenge of antimicrobial resistance through innovative solutions. It develops proprietary Binding Protein ingredients aimed at fortifying the gut microbiome, thereby reducing the risk of gastrointestinal infections in both humans and animals. Bactolife's platform is designed to neutralize harmful pathogens and their toxins while preserving beneficial microbes, thus promoting overall gut health. By enhancing gut microbiome modulation technologies, the company seeks to diminish reliance on traditional antimicrobials, ultimately improving health outcomes and contributing to the fight against antimicrobial resistance.

Latham BioPharm Group is a firm specializing in life sciences, offering comprehensive expertise in business development, program management, quality assurance, regulatory affairs, and strategic consulting. With a team that boasts an average of over 20 years of experience, including roles as senior executives in both startups and Fortune 200 companies, Latham BioPharm has a strong foundation in guiding clients through the complexities of product development. The company has a proven track record in biodefense and pandemic response, having successfully assisted clients in identifying and securing funding, managing programs, and monetizing opportunities across various sectors. Their services include strategy and portfolio analysis, market research, and connecting clients with target markets to enhance decision-making. Latham BioPharm's expertise has contributed to generating substantial government funding and licensing fees, positioning them as a key partner in advancing innovations in vaccines, therapeutics, medical devices, and diagnostics.

Aegis Life is a biotechnology company focused on advancing nucleic acid delivery technology, specifically through its proprietary platform known as fusogenix PLV. With over two decades of dedicated research and development, the company aims to facilitate the discovery, clinical development, and manufacturing of vaccines and therapeutics targeting infectious diseases. Aegis Life's innovative technology enables the rapid development of solutions to combat a range of health threats, including COVID-19 and other emerging contagions. Through its efforts, the company supports the pharmaceutical industry in addressing urgent public health challenges effectively.

Hyperfine is a pioneering medical device company known for developing Swoop, the first FDA-cleared point-of-care MRI system. Swoop is designed to enhance patient access to rapid diagnosis and treatment, regardless of socioeconomic factors or geographic location. This innovative portable MRI system operates at a lower magnetic field strength than traditional MRI machines, allowing for high-quality imaging in a variety of clinical environments. Swoop can be easily transported to a patient's bedside, requires only a standard electrical outlet, and is controlled via an iPad, facilitating quick scans that support critical decision-making in settings such as emergency departments and intensive care units. Hyperfine generates revenue through the sale of its MRI devices as well as service sales, which include subscriptions for bundled devices, maintenance, and software.

The Medicines for All Institute, operating under the auspices of the Virginia Commonwealth University School of Engineering.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, founded in 2016. It specializes in developing innovative therapeutic products aimed at treating and preventing serious infectious diseases. The company's pipeline includes several promising candidates, such as VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for HIV, and VIR-2020 for tuberculosis. Vir Biotechnology employs advanced technologies and scientific expertise to manipulate immune responses and enhance pathogen-host interactions. The company has established various collaborations and agreements with notable organizations, including the Bill & Melinda Gates Foundation, National Institutes of Health, and Alnylam Pharmaceuticals, among others. Additionally, it has a manufacturing agreement with Samsung Biologics for the production of SARS-CoV-2 antibodies aimed at potential COVID-19 treatment. Through its innovative approaches, Vir Biotechnology aspires to significantly reduce the burden of infectious diseases in the future.

Audere is a digital health nonprofit developing software to improve global health in underserved communities.

Smart Immune is a clinical-stage biotechnology company dedicated to advancing hematopoietic stem cell-based biotherapies aimed at improving the prognosis and quality of life for patients with severe diseases. The company's primary focus is on its innovative cell therapy program that utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This program is complemented by integrative developments in targeted conditioning, gene therapy, and genome editing, allowing for the creation of next-generation treatments. Smart Immune's approach aims to provide effective allogeneic T-cell therapies for patients suffering from life-threatening conditions, particularly hematological malignancies and primary immune deficiencies.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

Noze is a pioneering company in digital odor perception, recognized for creating an advanced digital nose that accurately detects and identifies odors in various real-world contexts. Leveraging cutting-edge machine perception technology and a specialized sensor developed from NASA innovations, Noze aims to enhance human health and wellbeing. The company's technology mimics the human olfactory system, allowing it to gather data on air quality and chemical footprints based on scent. This enables healthcare providers to monitor and predict health changes, diagnose diseases, and perform routine screenings through breath-based odor biomarkers. Ultimately, Noze is dedicated to facilitating real-time disease detection at any point-of-care, thereby significantly improving patient outcomes.

UW Medicine is a clinical research and healthcare system that provides a higher degree of healthcare for pre-med students. UW Medicine health professionals provide the most up-to-date care for each individual patient through these integrated programs, lead one of the world's largest and most comprehensive medical research programs, and provide innovative learning programs for students, trainees, and practitioners in the health professions. UW Medicine, as the region's only comprehensive clinical, research, and learning health system, provides a higher level of healthcare, ranging from primary and preventive care to the most highly specialized care for the most complex medical conditions.

VisualDx is a diagnostic clinical decision support system that aims to enhance diagnostic accuracy and improve patient safety. By integrating a curated medical image library with a powerful search engine, VisualDx provides clinicians with patient-specific answers in seconds. The platform is designed for both web-based and mobile use, facilitating point-of-care decisions and fostering patient engagement. It offers high-quality images that encompass a wide range of pediatric and adult medical conditions. VisualDx is utilized by over 2,300 hospitals, clinics, and medical schools globally, enabling healthcare professionals to make better and faster decisions for their patients.

LumiraDx Ltd, incorporated in 2016 and based in London, United Kingdom, is a next-generation point-of-care diagnostics company. It specializes in manufacturing an innovative diagnostic platform that provides a wide range of tests with lab-comparable performance. LumiraDx aims to transform healthcare by offering solutions that facilitate integrated, patient-centered care, enhancing safety, efficiency, and health outcomes. The company's diagnostic system includes a portable instrument, low-cost test strips, and seamless digital connectivity, making diagnostic-led care simpler and more accessible. LumiraDx operates in multiple countries, including the United States, Italy, Germany, and Sweden, with a significant portion of its revenue generated from the U.S. market.

Aspen Pharmacare Holdings Limited is a global specialty pharmaceutical company headquartered in Durban, South Africa. It manufactures and supplies a diverse portfolio of specialty, branded, and generic pharmaceutical products across more than 150 countries. The company operates through two main segments: Commercial Pharmaceuticals and Manufacturing. Aspen offers a range of products, including general anaesthetics, muscle relaxants, cytotoxic medicines, and injectable anticoagulants, with a focus on low molecular weight heparins. Additionally, Aspen engages in the contract manufacturing and supply of active pharmaceutical ingredients and finished dose pharmaceuticals for third parties. The company's extensive product offerings include oral solids, injectables, liquids, semi-solids, and biologicals. With a strong presence in various international markets, including Africa, Asia, Europe, and the Americas, Aspen continues to expand its operations through strategic acquisitions and partnerships. Founded in 1850, Aspen has established itself as a leading player in the pharmaceutical industry.

Touchlight Genetics Ltd. is a biotechnology company based in Leatherhead, United Kingdom, specializing in DNA therapies and technology. Founded in 2007, the company has developed the proTL synthetic DNA platform, which enables the production of closed linear DNA, known as doggybone DNA, without the need for bacterial fermentation. This innovative platform is designed for various applications, including veterinary vaccines, monoclonal antibodies, cancer and gene therapies, allergy treatments, RNA interference therapies, and stem cell reprogramming. Touchlight Genetics is led by a team with significant expertise in life sciences, including founder and CEO Jonny Ohlson and Non-Executive Chairman Clive Dix. The company has successfully established collaborations with prominent academic institutions such as Imperial College London and the University of Pennsylvania, enhancing its research capabilities and expanding its impact in the field of DNA vaccine development for oncology and infectious diseases.

Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products in women’s reproductive health.

Contro operates as an online platform facilitating secure, convenient access to sexual health products such as birth control and erectile dysfunction treatment in South Africa. Through its digital service, Contro enables users to consult with doctors remotely for prescriptions, which are then discreetly delivered monthly at no extra cost. Users enjoy a flexible subscription model, allowing them to cancel anytime without penalties.

Bayer is a multinational corporation with a focus on life science industries. It operates in three main business areas: Pharmaceuticals, Consumer Health, and Crop Science. Bayer Pharmaceuticals develops and markets a wide range of medicines, including those for cardiovascular diseases, oncology, and women's health. The Consumer Health division offers over-the-counter products and medical devices, while Crop Science provides crop protection products, seeds, and digital farming solutions. Bayer Animal Health, a part of the Crop Science division, is a global leader in animal health, offering a broad portfolio of products for the treatment and prevention of diseases in livestock and companion animals. The company's global presence and extensive product portfolio enable it to address various health challenges in humans, animals, and crops, contributing to a sustainable future.

Helium Health is a technology company focused on transforming healthcare in Africa by providing a comprehensive suite of software solutions for hospitals and clinics. The company specializes in electronic health record systems that facilitate the management of patient data and hospital operations. Its platform simplifies various processes, including doctor visits, prescriptions, and medical billing, making it accessible from any device. Additionally, Helium Health offers customizable forms and tools for monitoring healthcare trends, generating alerts, and producing reports. By leveraging technology, the company aims to create a modern and affordable healthcare system while aspiring to become the largest healthcare data exchange in Africa.

CQUIN is made up of representatives from ministries of health, implementing partners, civil society, associations of people living with HIV, academic institutions, and donor agencies that work with CQUIN to scale up DSD according to each country’s unique needs. The company encourages experience sharing, peer-to-peer learning, and collaborative issue solving. It allows member countries to obtain technical support from Columbia University's ICAP.

Bactolife is a company focused on addressing the global challenge of antimicrobial resistance through innovative solutions. It develops proprietary Binding Protein ingredients aimed at fortifying the gut microbiome, thereby reducing the risk of gastrointestinal infections in both humans and animals. Bactolife's platform is designed to neutralize harmful pathogens and their toxins while preserving beneficial microbes, thus promoting overall gut health. By enhancing gut microbiome modulation technologies, the company seeks to diminish reliance on traditional antimicrobials, ultimately improving health outcomes and contributing to the fight against antimicrobial resistance.

CaliberMRI is a platform that includes brain, breast, prostate, and custom phantoms, and companion automated quality control software. They provide services that include quantitative MRI, qmri, phantoms, quantitative medicine, radiology, breast cancer, and calibration.

Eleven Therapeutics is a biotechnology company leveraging artificial intelligence to advance medicinal nucleic acids, particularly focusing on RNAi therapies and mRNA therapeutics. The company employs AI-driven parallel functional testing and combinatorial chemistry to develop programmable molecules called SCSI-RNAs, which can target specific diseases or biological targets. Additionally, Eleven Therapeutics is pioneering extended durability mRNA therapeutics designed to address unmet medical needs in metabolic, endocrinologic, and infectious diseases. Their proprietary high-throughput AI-enabled screening platforms enhance the stability and targeted delivery of these nucleic acid molecules, ensuring superior durability and specificity.

Iconovo AB, based in Lund, Sweden, specializes in developing and licensing inhalation devices. It offers a range of dry powder inhalers, including ICOres, ICOcap, ICOone, and ICOpre, catering to generic pharmaceutical companies. With a focus on technical innovation, user-friendly design, and cost-efficiency, Iconovo aims to become a global leader in its field, targeting a multimillion turnover within five years.

Sapient enables the discovery of circulating small molecule biomarkers at unprecedented speed and scale. Leveraging next-generation mass spectrometry, biocomputational analysis, and large-scale human biology databases, its platform supports the rapid identification and validation of circulating biomarkers of health, disease, and drug response which are needed to align patients, disease biology, and specific therapies.

Flywheel.io is a cloud-based data management platform tailored for biomedical research and collaboration. Founded in 2012 and headquartered in Minneapolis, Minnesota, the company provides a suite of tools designed to enhance the workflow of scientists and researchers. Its platform supports medical imaging, scientific computation, and content management, enabling users to capture, manage, and analyze research data efficiently. By utilizing cloud scalability and automation, Flywheel facilitates collaborative research, machine learning applications, and multicenter studies, which help organizations streamline their research processes. The platform, featuring a modern web interface and extensible compute engine, aims to eliminate bottlenecks in innovation, allowing researchers to focus on scientific discovery rather than IT challenges.

SwipeRx is a digital platform designed for pharmacies that connects pharmaceutical manufacturers, pharmacies, and patients. It offers specialized healthcare logistics, negotiated pricing, and financing solutions, creating the largest digital pharmacy purchasing network. The platform generates insights that enhance collaboration among pharmacies, improve pharmacist education, and strengthen market access. Additionally, it optimizes commercial strategies and boosts operational efficiencies, providing real-time access to patient and sales data. By doing so, SwipeRx enables its clients to improve patient affordability, access, and adherence to medications.

Cardea Bio, Inc. is a biotechnology company based in San Diego, California, focused on developing and commercializing bioelectronics for research and diagnostics. Established in 2013, Cardea utilizes proprietary graphene-based digital biosensors to create advanced biosensor hardware, software, and molecular infrastructure, enabling precision healthcare through improved diagnostic capabilities. The company's product offerings include the AGILE R100, an innovative assay for drug discovery, and the AGILE R200, an automated high-throughput screening solution. Cardea's biosensors convert biomolecular interactions into digital data, allowing for real-time biological signal analysis and access to streaming multi-omics data. Their solutions cater to various applications in life sciences and healthcare, such as small molecule validation, antibody characterization, and biomolecular analysis.

Yemaachi Biotechnology is a company focused on advancing cancer diagnosis and treatment through innovative technology. Utilizing immunogenomics, bioinformatics, and artificial intelligence, Yemaachi aims to enhance the development of effective strategies for cancer detection and treatment. The company's platform is designed to improve patient outcomes and reduce the economic burden associated with cancer care. By combining these advanced technologies, Yemaachi seeks to provide more effective therapeutic solutions for cancer patients.

Butterfly Network, Inc. is a medical imaging company based in Guilford, Connecticut, that specializes in handheld ultrasound technology. Founded in 2011, the company has developed the world's first handheld, single-probe whole-body ultrasound system, known as Butterfly iQ, powered by its proprietary Ultrasound-on-Chip technology. This innovative device provides diagnostic imaging for various medical conditions affecting the cardiac, abdominal, urological, fetal, gynecological, and musculoskeletal systems. Butterfly Network aims to democratize access to medical imaging, particularly for the 4.7 billion people globally who lack access to ultrasound services. By integrating cloud-connected software with its ultrasound hardware, Butterfly enhances the clinical workflow, facilitating earlier detection and remote management of health conditions.

Particles for Humanity is a company dedicated to transforming early-stage medical technologies into practical products aimed at improving the quality of life for individuals in low-resource settings. The company focuses on developing a portfolio of healthcare solutions that address critical issues such as vaccination and malnutrition. By employing a rigorous product development process that incorporates input from end-users, Particles for Humanity aims to create financially sustainable products that meet the specific needs of underserved populations. Through its innovative approach, the company seeks to empower individuals to combat serious health challenges and enhance their overall well-being.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

Elarex, a Canadian healthcare technology company, specializes in developing and commercializing proprietary formulation technologies. Its flagship innovation, PT120, stabilizes biologicals, including live vaccines, enabling them to maintain full efficacy even when stored at 40°C, comparable to -80°C storage. This breakthrough allows for broader access to vaccines and biological drugs by facilitating transportation and storage in diverse environments, thereby enhancing global healthcare accessibility.

Providence Therapeutics Inc. is a biotechnology company based in Toronto, Canada, founded in 2015. The company specializes in the development and manufacture of messenger ribonucleic acid (mRNA) vaccines formulated in lipid nanoparticles. Providence Therapeutics focuses on personalized cancer therapies, notably creating mRNA vaccines that target specific tumor mutations to elicit an immune response against cancer cells, particularly for advanced ovarian cancer. In addition to its oncology initiatives, the company has developed vaccines for other diseases, including PTX-101 for cancer and PTX-COVID19-B and PTX-COVID19-T for COVID-19. Providence Therapeutics aims to address unmet medical needs by providing safe and effective vaccines and therapies to improve patient outcomes.

MyDawa is an online pharmacy that provides a convenient platform for individuals to purchase a wide range of high-quality medications and wellness products directly from their mobile devices. By connecting patients to drug stores, MyDawa facilitates affordable access to essential medications without imposing service fees, transaction charges, or delivery costs. This approach aims to streamline the pharmaceutical supply chain, addressing common challenges faced by consumers when sourcing health-related products. MyDawa’s innovative service offers a straightforward and efficient solution for obtaining necessary health items, thereby enhancing the overall customer experience in the healthcare sector.

Philips, established in 1891, is a Dutch diversified technology company that focuses on improving people's health and well-being through meaningful innovation. The company operates in three segments: Diagnosis & Treatment, Connected Care, and Personal Health. Philips Healthcare, a division of Philips, is a leader in diagnostic imaging, image-guided therapy, patient monitoring, health informatics, consumer health, and home care. It offers a wide range of products such as CT scanners, MRI machines, ultrasound equipment, and more, aiming to enhance preventive care, diagnosis, and treatment. Additionally, Philips Research drives innovation across these segments, while the Philips Foundation focuses on reducing healthcare inequality through access to quality care for disadvantaged communities. The company also provides lighting solutions and consumer lifestyle products, including personal care and oral healthcare items.

Inventprise is a biotechnology company focused on the development of GMP vaccines, particularly a 25-valent pneumococcal conjugate vaccine (PCV). Founded in 2012 and based in Redmond, Washington, the company aims to provide large-scale vaccine supplies to low- and middle-income countries, significantly supported by funding from the Bill and Melinda Gates Foundation. In addition to its vaccine development efforts, Inventprise offers comprehensive outsourcing solutions for biopharmaceutical manufacturing, which include quality control assays, batch records, and necessary documentation. The company also provides in-person training and operates a fully equipped quality control laboratory for testing vaccine identity, potency, purity, and stability, thereby addressing health inequalities and promoting healthier lives globally.

Brightseed, Inc. is a pioneering biosciences company based in San Francisco, California, founded in 2017. It specializes in the discovery of bioactive compounds in plants that have beneficial effects on human health, particularly for chronic disease management. Utilizing its proprietary Forager platform, which incorporates artificial intelligence and machine learning, Brightseed accelerates the identification and validation of these naturally occurring compounds, transforming what was once a lengthy process into a matter of months. By mapping bioactives to specific health outcomes, Brightseed provides valuable insights and science-backed solutions to partners across the consumer health continuum. The company's innovative approach aims to illuminate the connections between nature and human health, ultimately improving quality of life and addressing health challenges through the exploration of previously uncharted plant compounds.

Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing proprietary therapeutics for chronic diseases. The company utilizes its innovative ProNeura technology, a long-term drug delivery platform, to create products that maintain stable blood levels of medication over extended periods. Titan's principal product, Probuphine, is the first slow-release implant formulation of buprenorphine, designed for the outpatient treatment of opioid dependence. This implant allows for consistent medication delivery for up to six months, enhancing patient compliance and reducing the risk of misuse associated with traditional sublingual formulations. Additionally, Titan is developing ProNeura-Ropinirole, an implant for treating Parkinson’s disease, and a triiodothyronine implant for hypothyroidism. Established in 1992, Titan is committed to addressing serious medical disorders through its advanced drug delivery solutions.

Eleven Therapeutics is a biotechnology company leveraging artificial intelligence to advance medicinal nucleic acids, particularly focusing on RNAi therapies and mRNA therapeutics. The company employs AI-driven parallel functional testing and combinatorial chemistry to develop programmable molecules called SCSI-RNAs, which can target specific diseases or biological targets. Additionally, Eleven Therapeutics is pioneering extended durability mRNA therapeutics designed to address unmet medical needs in metabolic, endocrinologic, and infectious diseases. Their proprietary high-throughput AI-enabled screening platforms enhance the stability and targeted delivery of these nucleic acid molecules, ensuring superior durability and specificity.

Sunflower Therapeutics is a biotechnology company specializing in next-generation protein manufacturing solutions. Its mission is to enhance global patient access to biological medicines by developing and implementing advanced technologies suitable for worldwide application. The company employs strain engineering, integrated process development, and automated multi-product facilities to create efficient and scalable production methods for proteins. Sunflower Therapeutics prioritizes values such as wellness, integrity, ethics, equity, community, and efficiency in its operations.

CRISPR Therapeutics AG is a biotechnology company based in Zug, Switzerland, dedicated to developing transformative gene-based medicines for serious human diseases using CRISPR/Cas9 technology. This revolutionary gene-editing platform allows for precise changes to genomic DNA. The company's portfolio includes therapeutic programs targeting hemoglobinopathies, oncology, regenerative medicine, and rare diseases. Their lead product candidate is CTX001, a gene-edited therapy for transfusion-dependent beta thalassemia or severe sickle cell disease, which has been approved as Casgevy in collaboration with Vertex Pharmaceuticals. Additionally, CRISPR Therapeutics is developing CTX110, an allogeneic CAR-T therapy targeting CD19-positive malignancies, and other programs like CTX120 for multiple myeloma and CTX130 for solid tumors and hematologic malignancies. The company also engages in regenerative medicine programs for diabetes and genetic disease treatments such as glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. CRISPR Therapeutics has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc.

Particles for Humanity is a company dedicated to transforming early-stage medical technologies into practical products aimed at improving the quality of life for individuals in low-resource settings. The company focuses on developing a portfolio of healthcare solutions that address critical issues such as vaccination and malnutrition. By employing a rigorous product development process that incorporates input from end-users, Particles for Humanity aims to create financially sustainable products that meet the specific needs of underserved populations. Through its innovative approach, the company seeks to empower individuals to combat serious health challenges and enhance their overall well-being.

Icosavax, Inc. is a biotechnology company based in Seattle, Washington, founded in 2017. The company specializes in developing vaccines utilizing its proprietary virus-like particle (VLP) platform technology. This innovative approach allows for the multivalent, particle-based display of complex viral antigens, which is aimed at generating broad and durable immune responses. Icosavax focuses primarily on life-threatening respiratory diseases, with its lead vaccine candidate, IVX-121, targeting respiratory syncytial virus (RSV) in older adults. The company's pipeline also includes candidates for human metapneumovirus (hMPV) and SARS-CoV-2, reflecting its commitment to advancing vaccine solutions for infectious diseases.

Ilara Health is a company based in Nairobi, Kenya, founded in 2018, that specializes in the development and distribution of AI-powered diagnostic devices aimed at primary care doctors in peri-urban and rural clinics. The company's innovative technology platform integrates miniature diagnostic devices with software that connects to an electronic medical record system, allowing healthcare providers to efficiently manage patient data. By focusing on accurate and affordable diagnostics, Ilara Health seeks to enhance healthcare accessibility and quality for rural populations in Africa, addressing the challenges posed by a fragmented healthcare infrastructure.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products in women’s reproductive health.

Sapient enables the discovery of circulating small molecule biomarkers at unprecedented speed and scale. Leveraging next-generation mass spectrometry, biocomputational analysis, and large-scale human biology databases, its platform supports the rapid identification and validation of circulating biomarkers of health, disease, and drug response which are needed to align patients, disease biology, and specific therapies.

HJF Medical Research International is an NGO that supports international programs advancing medical research and HIV prevention.

Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products in women’s reproductive health.

Montreal Heart Institute is a specialty hospital dedicated to the development of cardiology.

Particles for Humanity is a company dedicated to transforming early-stage medical technologies into practical products aimed at improving the quality of life for individuals in low-resource settings. The company focuses on developing a portfolio of healthcare solutions that address critical issues such as vaccination and malnutrition. By employing a rigorous product development process that incorporates input from end-users, Particles for Humanity aims to create financially sustainable products that meet the specific needs of underserved populations. Through its innovative approach, the company seeks to empower individuals to combat serious health challenges and enhance their overall well-being.

Vaxxas is a biotechnology company based in Brisbane, Australia, focused on developing a novel needle-free vaccination technology. Established in 2011, Vaxxas employs proprietary dry-coating technology that significantly reduces or eliminates the need for refrigeration during the storage and transportation of vaccines, thereby addressing logistical challenges associated with the cold chain. The company's innovative delivery system features an array of vaccine-coated micro projections that penetrate the outer layers of the skin when applied with a specialized applicator device. This method allows for the direct deposition of vaccines among a dense population of immune cells in the skin, potentially transforming the global delivery of vaccines.

Inovio Pharmaceuticals, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of DNA medicines aimed at treating, curing, and protecting individuals from diseases related to human papillomavirus (HPV), cancer, and infectious diseases. The company's innovative SynCon immunotherapy design enables the immune system to target cancerous cells while providing cross-strain protection against various pathogens. Inovio's clinical studies focus on HPV-associated precancers, cancers, and other disorders, as well as diseases such as glioblastoma multiforme, HIV, and COVID-19. The company has developed a proprietary delivery system that allows DNA medicine to be introduced directly into cells, producing a strong immune response. Notably, its lead candidate, VGX-3100, is undergoing Phase 3 trials for precancerous cervical dysplasia, having shown promise in earlier trials by effectively clearing high-risk HPV strains. Founded in 1979 and headquartered in Plymouth Meeting, Pennsylvania, Inovio collaborates with various partners, including major pharmaceutical companies and research institutions, to advance its clinical initiatives and expand its therapeutic reach.

Centre for Innovation in Regulatory Science is a neutral, independently managed UK-based subsidiary company, forming part of the Clarivate Analytics group. CIRS provides an international forum for industry, regulators, HTA and other healthcare stakeholders to meet, debate and develop regulatory and reimbursement policy through the innovative application of regulatory science and to facilitate access to medical products. This is CIRS’ purpose. CIRS is operated solely for promotion of its purpose. The organisation has its own dedicated management and advisory boards, and its funding is derived from membership dues, related activities, special projects and grants.

Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with an additional office in Conshohocken. Founded in 1999, the company focuses on the discovery and development of innovative T cell receptor-based therapeutics aimed at addressing significant unmet medical needs in cancer, viral diseases, and autoimmune diseases. Immunocore specializes in engineering T cell receptors (TCRs) and linking them to antibody fragments, which has led to the development of its lead product candidate, IMCgp100, currently undergoing clinical trials for metastatic melanoma. The company's proprietary TCR technology platform is validated and designed for efficient manufacturing, supporting both clinical and commercial supply. Immunocore was previously known as Avidex Limited before adopting its current name in 2008.

Biological Dynamics Inc. is a healthcare company based in San Diego, California, that specializes in developing a proprietary technology platform for the direct and selective capture of large necrotic particles from physiological solutions such as whole blood, serum, and plasma. This platform facilitates the detection of diseases, particularly cancers, in their earliest stages by enabling access to native-state biomarkers and nanoparticles for multiomics applications. The company offers various products and services, including the TR(ACE) Assay for monitoring treatment responses in cancer, tissue-based molecular and cfDNA liquid biopsy testing for personalized medicine, and a biomarkers program aimed at drug development for Alzheimer's disease. Additionally, Biological Dynamics provides clinical laboratory services, including molecular and next-generation sequencing, and supports applications in autoimmune diseases, transplant rejection, and traumatic brain injury. Founded in 2008, the company is dedicated to improving global health outcomes through innovative diagnostic solutions.

Macro-Eyes, Inc. is a machine learning company focused on enhancing access to healthcare through its innovative solutions. Its primary product, Sibyl, employs artificial intelligence for intelligent patient scheduling, which has shown a capability to improve patient utilization by 15%, enabling healthcare providers to see more patients without extending clinical hours. This technology is built on extensive research and deployment of AI for clinical decision support at prominent institutions, including Stanford University and major health systems in the United States. The company has garnered support from the Bill & Melinda Gates Foundation to develop a predictive supply chain for health, aimed at optimizing resource allocation at individual health facilities and pharmacies to prevent stock-outs and reduce waste. Additionally, Macro-Eyes is collaborating with the California Primary Care Association to implement Sibyl across 1,800 health facilities, thereby furthering its mission to increase access to life-saving care.

VisualDx is a diagnostic clinical decision support system that aims to enhance diagnostic accuracy and improve patient safety. By integrating a curated medical image library with a powerful search engine, VisualDx provides clinicians with patient-specific answers in seconds. The platform is designed for both web-based and mobile use, facilitating point-of-care decisions and fostering patient engagement. It offers high-quality images that encompass a wide range of pediatric and adult medical conditions. VisualDx is utilized by over 2,300 hospitals, clinics, and medical schools globally, enabling healthcare professionals to make better and faster decisions for their patients.

1mg is an Indian digital healthcare platform, launched in 2015, that operates from Gurgaon, Haryana. It aims to make healthcare more accessible, understandable, and affordable. The platform enables users to find detailed information about prescribed medicines, buy them, and search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a doctor platform to help users find suitable healthcare professionals and a diagnostics service for transparent and cost-effective lab tests. The company empowers consumers and caregivers to choose the most appropriate healthcare services at competitive prices.

Landcent is a company dedicated to combating global infectious diseases, with a focus on malaria. It develops and delivers affordable, sustainable solutions that are safe for large-scale use, aiming to accelerate the fight against these diseases and ultimately eliminate them.

MedinCell S.A. is a pharmaceutical company focused on developing innovative therapeutic solutions through its proprietary BEPO technology, which facilitates long-acting injectable products utilizing biodegradable polymers and a biocompatible solvent. Based in Jacou, France, the company is engaged in ongoing research and development to optimize the efficiency and accessibility of medical treatments across various therapeutic areas. MedinCell's product pipeline includes several candidates, such as mdc-IRM, a subcutaneous injection for schizophrenia currently in Phase III trials, and mdc-CWM, an intra-articular injection aimed at treating pain and inflammation. Additionally, the company is exploring formulations like mdc-WWM for contraception and mdc-ANG for central nervous system disorders, alongside other candidates targeting pain management and organ transplant applications. Through its advancements in controlled, long-acting injectables, MedinCell aims to enhance treatment outcomes for patients.

RJH Biosciences is a biotechnology company dedicated to the development of transfection reagents and delivery agents for nucleic acids. It focuses on creating innovative systems that effectively transport various types of nucleic acids to human cells and cell lines, particularly targeting blood cancers and the modification of immune cells. By advancing these technologies, RJH Biosciences aims to enable healthcare professionals to harness the therapeutic potential of nucleic acids, ultimately contributing to the development of new medical treatments. The company distributes its products through its website and engages in projects that further enhance its offerings in the field of biotechnology.